EASD 2019 Archives - Endocrinology Advisor

European Society for the Study of Diabetes 55th Annual Meeting

Complete Coverage

Dapagliflozin May Lower Risk for Worsening Heart Failure

For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes.
Next post in EASD 2019